Dec 8, 2015

Multiscale Modeling of Cancer

BioRxiv : the Preprint Server for Biology
Kerri-Ann NortonAleksander S Popel


Breast cancer remains the second leading cause of cancer death in women, exceeded only by lung cancer. Specifically, triple-negative breast cancer (TNBC) has the worst prognosis, as it is more invasive and lacks estrogen, progesterone, and HER2 receptors that can be targeted with therapies. Due to the need for effective therapies for this type of breast cancer, it is critical to develop methods to (1) understand how TNBC progresses and (2) facilitate development of effective therapies. Here, we describe a multiscale model focusing on tumor formation. Our approach uses multiple scales to investigate the progression and possible treatments of tumors.

  • References
  • Citations


  • We're still populating references for this paper, please check back later.
  • References
  • Citations


  • This paper may not have been cited yet.

Mentioned in this Paper

ErbB-2 Receptor
Cessation of Life
Triple Negative Breast Neoplasms
Progesterone [EPC]
Carcinoma of Lung
Progesterone Measurement
ERBB2 gene
ERBB2 wt Allele

About this Paper

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

American Thoracic Society: Clinical Problems

This feed has been developed in conjunction with the American Thoracic Society for the benefit of its Clinical Problems Assembly. It highlights new and impactful papers on clinical therapeutics, diagnoses, and practices pertaining to respiratory disease.